Magazine Article | February 1, 2019

The Drug-Delivery Company That Partnerships Built

Source: Life Science Leader

By Cindy Dubin, Contributing Writer

Partnerships have been important to Arcturus Therapeutics, especially during the early phases of growth. Prior to becoming a public company in 2017, Arcturus was funded primarily (80 perecent) by strategic partners. “Non-dilutive monies, during the early stages of a company, provide essential funding and validate the science,” says Joseph Payne, president and CEO of Arcturus, a preclinical RNA medicines company. “Normally a company raises money, does its science, and hopes to get a deal. We were the inverse of that, getting money early from strategic partnerships and then transitioning to becoming a public company.”

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: